喉癌术后喉狭窄患者喉重建术后的嗓音分析

目的:分析喉癌术后喉狭窄患者行颈前旋转肌皮瓣喉重建术后的嗓音康复情况.方法:应用Dr.Speech嗓音分析系统对19例喉癌术后喉狭窄患者喉重建术后的嗓音参数,包括基频(F0)、基频微扰(Jitter)、振幅微扰(Shimmer)及声门噪声能量(NNE)值进行分析,并与喉重建术前以及成人喉乳头状瘤15例、声带息肉20例、正常人20例进行对比.结果:喉癌术后喉狭窄患者喉重建后的F0较术前有显著上升(P＜0.05),而Jitter、Shimmer及NNE值较术前均明显下降(P＜0.05);F0较喉乳头状瘤组有显著下降(P＜0.05);与声带息肉组相比,F0、Jitter均显著下降(P＜0.05);与正常组比较,Jitter、Shimmer及NNE值均明显上升(P＜0.05).结论:喉癌术后喉狭窄患者行颈前旋转肌皮瓣喉重建术后的嗓音较术前有明显改善,能获得较好的嗓音功能.     

喉部分切除转门肌皮瓣喉重建术的嗓音学观察

目的:观察声门癌扩大部分喉切除转门肌皮瓣修复缺损喉腔术后患者的嗓音恢复情况.方法:应用计算机Dr. Speech嗓音测试康复系统嗓音分析法评价患者手术前后的嗓音变化.结果:术后1个月,患者嗓音各项参数值(Jitter、Shimmer及NNE)与术前相比略差,但除NNE (P<0.05)外均无统计学意义(P>0.05);术后半年,患者嗓音各项参数值综合评价好于术前.结论:转门肌皮瓣修复扩大部分喉切除术后喉腔缺损,可获得较好的嗓音质量.     

声门型喉癌患者喉部分切除术后发声功能评估

目的:研究声门型喉癌患者喉部分切除发音功能重建术式与术后嗓音质量的关系。方法:采用Dr.Speech4.0嗓音分析软件,对48例声门型喉癌喉部分切除采用室带下拉、双蒂接力肌、颈阔肌皮瓣修复术患者术前1天、术后6个月、术后1年行发声功能测试,对基频、频率微扰、振幅微扰、标准化噪声能量、最大发声时间进行分析。结果:各组患者术后嗓音质量逐渐好转,术后6个月～1年嗓音逐渐进入稳定期。结论:发声功能恢复与手术方式及重建方法密切相关,创伤大小、修复体功能特性、新声门形态以及发音时新声门能否良好闭合等因素直接影响着术后嗓音质量。手术修复应尽量减少术后声门上结构代偿振动参与发音导致的嗓音质量下降。     

全喉切除术后喉再造3例

喉再造术是利用颈前转门肌皮瓣技术 ,恢复因喉部恶性肿瘤行全喉切除术后患者喉的发音功能、吞咽功能、呼吸功能 ,通过锻炼恢复经鼻呼吸 ,恢复嗅觉 ,加强味觉等的一种术式。 2 0 0 1年 11月至 2 0 0 1年 12月我院耳鼻咽喉科实施此项手术 ,通过 3例喉再造手术治疗 ,患者成功恢复了喉的呼吸、吞咽保护和发音三大功能。现报告如下。1　临床资料1 1　病例报告例 1,男 ,5 6岁。因声带癌于 1998年 5月在外院行全喉切除术 ,术后放疗 3次 ,量不详 ,未做化疗 ,曾行“发音扣手术”失败 ,现偶有食道音。术前一般情况良好 ,心肺腹检查未见明显异常 ,辅助…     

改良垂直部分喉切除术治疗声门型喉癌的疗效观察

目的 探讨改良垂直部分喉切除术治疗声门型喉癌临床疗效.方法 选取商丘市第一人民医院2011年1月至2014年8月收治声门型喉癌患者共70例,采用随机区组法分为常规组35例和改良组35例.常规组患者采用常规垂直部分喉切除术,改良组患者采用改良垂直部分喉切除术,比较两组患者发音功能和吞咽功能恢复情况、术后拔管率及随访24个月患者生存率等.结果 改良组患者发音功能和吞咽功能恢复有效率高于常规组,差异有统计学意义(P<0.05);改良组患者术后拔管率高于常规组,差异有统计学意义(P<0.05);两组患者出院后随访24个月,两组患者生存率比较差异无统计学意义(P>0.05).结论 相较于常规垂直部分喉切除术,改良垂直部分喉切除术治疗声门型喉癌可有效促进发音功能、吞咽及呼吸功能恢复,改善生活质量,且不降低远期生存率.     

水平垂直部分喉切除术疗效分析

探讨29例T3期声门上型和跨声门型喉癌,行水平垂直部分喉切除术治疗声门上型和跨声门型喉癌的疗效.结果:3年生存率为72.4%,5年生存率为48.3%,术后3个月拔管率为96%.在正确掌握手术适应证和喉重建技巧,水平垂直半喉切除术3～5年生存率不低于全喉切除术,并且保留了吞咽和发音功能.     

喉部分切除术后喉功能重建60例临床分析

目的：探讨喉部分切除术后喉功能重建方法的选择与应用。方法：对60例T2、T3及T4喉癌患者行喉部分切除术的术式及修复方法进行了回顾性分析。结果：60例中58例获得随访,主要应用颈前皮瓣、喉腔及梨状窝黏膜、胸舌骨肌膜瓣、甲状软骨膜及会厌软骨等修复喉结构,总体术后拔管率为81.7%,均获得了较好的吞咽及发音功能。喉声门区癌和喉声门上区癌3年和5年生存率分别为87.5%、70%和65%、50%。结论：在彻底切除病变的基础上,尽可能保留正常喉组织,保全喉功能,有利于患者恢复良好的吞咽和发音功能,提高了患者的生存质量。     

喉部分切除术治疗喉癌的探讨(附11例报道)

本文报告喉部分切除术治疗喉癌11侧,其中声门上癌4例,声门癌6例,梨状窝癌1例。病理类型鳞癌10例,腺癌1例。UICC 的TNM 分类法T_1N_0M_0 4例,T_2N_0M_0 5例,T_3N_0M_0 1例,T_3N_1M_0 1例。施行术式包括喉裂开术,侧前半喉切除术、水平上半喉切除术、喉次全切除加发音重建、梨状窝癌切除加同侧颈淋巴结清扫术等。术后无严重并发症,喉功能保存良好,全部恢复吞咽功能,喉发音100%。随访5个月至5年,3年生存率54.5%(6例)。     

喉部分切除声门重建术：附11例报告

报告喉部分切除声门重建术11例,均为喉声门区T_1～T_2鳞状上皮癌,其中1例伴有一侧喉咽部侵犯,还加作颈功能廓清术。所有病例采用本术治疗,喉功能(呼吸、吞咽、发音)恢复满意,随访1/2～4年无一例复发。     

保留喉功能的喉癌切除术（附16例报告）

目的探讨保留喉功能的喉癌切除术的可行性及部分喉切除后的缺损修复新方法的应用,重建良好的喉功能。方法声门型喉癌患者16例,根据切除的肿瘤范围及创面大小,应用甲状软骨双蒂肌软骨膜瓣修复喉腔13例,其中L2例、T211例;应用颈阔肌皮瓣修复喉腔3例,其中T2 1例、T32例。结果总拔管率为93．8％（15／16）。全部病例术后保存了发音功能,与正常状态比较,部分病例存在轻、中度声嘶,但发音清晰流畅,无交谈困难,均能用语言进行交流,患者均恢复了良好的吞咽及发音功能。结论甲状软骨双蒂肌软骨膜瓣、颈前颈阔肌皮瓣等用于修补垂直部分喉切除后的喉腔缺损,均能较好地重建喉形态及恢复喉功能。     

APPLICATION OF LORNOXICAM TO PATIENT-CONTROLLED ANALGESIA IN PATIENTS UNDERGOING ABDOMINAL SURGERIES

FOR anesthesiologis s ,treatingpostoperativepainhas alwaysbeen a problem.Althoughopioidshave been provedtobe effective,theirsideeffectscouldnotbeignored.With thedevelopmentofscienceand pharmacology,many drugs with aspectsof satisfactoryanalgesicefficacyand couldbe welltoleratedby patientshave been developed.And lornoxicamisone of them, which isa non-steroidalanti-inflammatorydrug (NSAID ), with analgesic, anti-infl-ammatory,andantipyreticproperties.Itseliminationhalf-time(3 to 5 hours) isle…     

Dr.Zhang Ren''''s Experience in the Acupuncture Treatment of Different Diseases with the Same Therapeutic Principle

Dr.Zhang Ren,the chief physician,is the chairman of Shanghai Acupuncture and Moxibustion Association.Having been engaged in medicine for about 40 years,he is experienced in treating various intractable diseases.In his long years of clinical practice,he advocates taking the TCM differentiation as the basis to seek for the acupuncture method for treatment of modern intractable diseases.The author of this essay had the fortune to follow Dr.Zhang in study.The following is a summary of Dr.Zhang's experience in the acupuncture treatment for different intractable diseases with the same therapeutic principle.     

Luo Lingjie''''s Experience in Treating Chronic Nephropathy

In treating chronic nephropathy,Luo Lingjie,a chief physician,pays attention to regulating the balance between yin and yang,treating infection if present,and removing pathogenic factors.He prescribes gentle drugs and uses carefully strongly warming-tonifying ones,emphasizes the importance of persuading the patient to persist in treatment with medication and nurse one's health for recuperation,and is good at combined use of TCM and western medicine therapy and brings the merits of various therapies into full play,with obvious theraoeutic effects.     

Acupuncture Combined with Spinal Tui Na for Treatment of Primary Dysmenorrhea in 30 Cases

Objective: To observe the therapeutic effects in acupunture treatment of primary dysmenorrhea combined with spinal Tui Na, and study its mechanism. Methods: Thirty cases of the treatment group were treated by acupuncture combined with spinal Tui Na, and thirty cases in the control group were treated by routine acupuncture. Results: The total effective rate was 93.3% in the treatment group, and 73.3% in the control group, with a significant difference between the two groups (P<0.05). Conclusions: Acupuncture combined with spinal Tui Na has good prospects for treatment of primary dysmenorrhea.     

猪肺磷脂注射液联合经鼻持续气道正压通气对呼吸衰竭早产儿的临床疗效及肌酸激酶同工酶活性的影响

目的 探讨猪肺磷脂注射液联合经鼻持续气道正压通气(NCPAP)对呼吸衰竭早产儿的临床疗效及肌酸激酶同工酶活性(CK-MB)的影响.方法 选取呼吸衰竭早产儿80例,分为观察组和对照组各40例.对照组采用NCPAP给氧治疗,观察组给予NCPAP给氧联合猪肺磷脂气管内给药.观察两组患儿治疗前及治疗12h、24 h后PaO2、PaCO2、血氧饱和度(SaO2)、pH的变化情况,检测治疗前及治疗5d后血清CK-MB水平;评估两组患儿的临床治疗效果.结果 两组患儿PaO2、PaCO2、SaO2、pH比较,差异均有统计学意义(P＜0.05),其中观察组治疗后的PaO2、SaO2、pH均高于对照组,PaCO2则低于对照组.两组的PaO2、SaO2、pH均随观察时间延长而升高(P＜0.05),PaCO2均随观察时间的延长而降低(P＜0.05).观察组治疗有效率为87.5％,显著高于对照组的70.0％ (P ＜0.05).治疗5d后两组患儿血清CK-MB水平均较前降低(P＜0.05),且观察组明显低于对照组(P＜0.05).结论 猪肺磷脂注射液气管内给药联合NCPAP可以显著降低呼吸衰竭早产儿CK-MB的含量,提高治疗有效率,起到很好的呼吸循环支持作用.     

Survey and practice of reporting quality of randomized controlled clinical trials on traditional Chinese medicine

Evidence obtained from randomized controlled trials （RCTs） has been generally accepted as the gold standard in the evaluation of clinical effectiveness. Readers need to understand the trial design, implementation, results, analysis and interpretation, so as to fully Jnderstand the results of RCTs. Thus, the investigators of RCTs have to report these items in a complete, accurate and clear manner. Since 1998, we have conducted several evaluations on the reporting quality of RCTs published in Chinese journals on traditional Chinese medicine （TCM） and results have shown that there is an urgent need for higher quality RCTs on TCM.     

TCM Treatment of Ankylosing Spondylitis by Tonifying the Kidney and Strengthening the Governor Vessel

Ankylosing spondylitis is a chronic and progressive disorder with inflammation mainly involving the central axis joints. It mainly affects the cervical spine and the lumbosacral area, with the pathogenesis closely related to the kidney and the Governor Vessel (GV). TCM holds that the syndrome is deficiency in origin and excess in superficiality, which is due to insufficiency of the kidney, deficiency of GV, and blocking of the channels with the invasion of exogenous evil, leading to poor circulation of qi and blood and malnutrition of the bones, muscles and joints. The TCM method of tonifying the kidney and strengthening GV to regulate circulation of qi and blood and check the arthralgia pain should be adopted, with the Kidney-Tonifying and GV Strengthening Decoction (益肾强督汤) prescribed.     

IMPROVING P-gp EXPRESSION IN HUMAN MONONUCLEAR CELLS IN VITRO TRANSFECTED BY MULTIDRUG RESISTANCE-1 mRNA

CHEMOTHERAPY playsa greatrolein the treat- ment of malignanttumors,especiallyingynecolo- gicalones.But inanticancerchemotherapy,leuko-cytopeniaisfrequentlytheprimarydose-limitingsideeffect factor.Moreover,cancersarefrequentlychemoresistantbe-causeof overexpressionof P-glycoprotein(P-gp), which isencodedby multidrugresistancegene (MDR1 ) and detectableinup to50% ofhuman cancersand renderscellsresistancetoanticancerdrugs.The safetyand potentialtherapeuticbenefitof mdr1 gene transferredto h…